Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review

Abstract

PEM is an antifolate antineoplastic agent with a broad-spectrum activity in locally advanced or metastatic NSCLC. It has been shown that PEM allows longer survival. The risk of acute or chronic kidney disease may be one of the prices to be paid for this success.